Company Overview * Industry: Vaccine * Company: Aimei Vaccine * Market Position: Aimei Vaccine is a leading vaccine company in China with a strong technical platform and full industrial chain. It holds four vaccine production licenses and has five products approved for market sales. * Key Points: * Aimei Vaccine has a mature technology platform with five platforms, and is one of the two companies in China approved to establish P3-level human vaccine enterprises. * The company's product pipeline covers the top ten global blockbuster vaccines, with eight commercial products and 21 in development. * Aimei Vaccine has four vaccine production bases across China, with a total of 3+7 research teams and seven production lines. * The company has a strong research and development team, with 39 invention patents and numerous utility model patents. Product Pipeline * Key Products: * Pneumococcal Conjugate Vaccine: Aimei Vaccine is focusing on the development of pneumococcal conjugate vaccines, including 13-valent, 20-valent, and 24-valent products. * Meningococcal Conjugate Vaccine: Aimei Vaccine is developing a new-generation meningococcal conjugate vaccine, as well as a global innovative vaccine product for GBS. * Influenza Vaccine: Aimei Vaccine is developing a novel MDCK cell influenza vaccine with a short production cycle and high efficacy. * Rabies Vaccine: Aimei Vaccine is developing a novel rabies vaccine with a single or two-dose regimen, as well as a global innovative rabies vaccine. * Herpes Zoster Vaccine: Aimei Vaccine is developing a herpes zoster vaccine using the MR technology platform, which has shown excellent cell-mediated immune effects. * RSV Vaccine: Aimei Vaccine is developing an RSV vaccine using the MR technology platform, which has shown good cross-protection effects against multiple strains. * Hand, Foot, and Mouth Disease Vaccine: Aimei Vaccine is developing a bivalent vaccine that covers both the 71st serotype and the A16 serotype, which is a global innovative vaccine product. * Development Progress: * Aimei Vaccine has submitted the registration application for 13-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine. * The clinical application materials for 23-valent pneumococcal conjugate vaccine and inactivated rabies vaccine have been submitted. * The clinical application materials for herpes zoster vaccine and RSV vaccine have been submitted. * The bivalent hand, foot, and mouth disease vaccine has obtained a clinical approval. Financial Performance * Revenue: Aimei Vaccine's revenue is mainly derived from its existing products, including rabies vaccine and hepatitis B vaccine. * Research and Development: Aimei Vaccine has a strong focus on research and development, with research and development expenses accounting for 53.6% of its sales revenue. * Profitability: Aimei Vaccine aims to achieve profitability in 2024, depending on the control of research and development expenses. Future Outlook * Internationalization: Aimei Vaccine is actively promoting the internationalization of its products, focusing on developing countries. * Innovation: Aimei Vaccine will continue to invest in research and development, focusing on innovative vaccine products and the MRN technology platform. * Growth: Aimei Vaccine aims to achieve a second growth curve in the next 3-5 years, driven by the launch of new products and the expansion of its market share.
艾美疫苗20240625